NEW YORK (TheStreet) -- Nanosphere (NSPH) plummeted to a 52-week low of 92 cents on Thursday after the molecular diagnostic company reported second-quarter earnings and issued full-year revenue guidance that came up short of analysts' expectations.
The company reported a net loss of 13 cents a share, slightly wider than the consensus estimate of 12 cents a share. Revenue rose 44% year-over-year to $2.7 million, well short of analysts' expectations of $3.9 million.
Nanosphere also reduced its full-year revenue guidance to $14 million and 175 to 200 new customer placements, down from a range of $19 million to $20 million and 200 new customer placements. Analysts expect revenue of $19.31 million for the fiscal year.
The stock was down 33.09% to 95 cents at 1:09 p.m. More than 3.5 million shares had changed hands, compared to the average volume of 1,039,880.
Separately, TheStreet Ratings team rates NANOSPHERE INC as a Sell with a ratings score of D-. TheStreet Ratings Team has this to say about their recommendation:
"We rate NANOSPHERE INC (NSPH) a SELL. This is driven by several weaknesses, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and generally disappointing historical performance in the stock itself."
You can view the full analysis from the report here: NSPH Ratings Report
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.